迈瑞医疗(300760) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥8,237,179,005, representing a decrease of 12.12% compared to ¥9,372,811,209 in the same period last year[3] - Net profit attributable to shareholders was ¥2,628,580,553, down 16.81% from ¥3,159,898,674 year-over-year[3] - Basic earnings per share were ¥2.1698, reflecting a decline of 16.89% from ¥2.6107 in the previous year[3] - Operating profit decreased to CNY 3,048,076,802, down 14.7% from CNY 3,572,278,524[23] - Net profit for the period was CNY 2,692,551,030, a decline of 15% from CNY 3,161,790,726[23] - The total comprehensive income for the period was ¥2,820,232,973, a decrease from ¥3,045,528,321, reflecting a decline of about 7.4%[24] - The total comprehensive income attributable to the parent company was ¥2,750,725,810, down from ¥3,049,956,378, indicating a decrease of about 9.8%[24] Cash Flow and Assets - The net cash flow from operating activities decreased by 47.83%, amounting to ¥1,494,408,057, primarily due to a reduction in cash received from sales[6] - The net cash flow from operating activities was ¥1,494,408,057, significantly lower than ¥2,864,694,162 in the previous period, reflecting a decline of approximately 47.8%[26] - Cash and cash equivalents at the end of the period totaled ¥15,954,841,645, down from ¥21,085,454,505, a decrease of about 24.5%[27] - The company received cash from sales of goods and services amounting to ¥8,732,237,374, compared to ¥9,929,908,497 in the previous period[25] - The cash outflow for operating activities was ¥7,941,750,662, an increase from ¥7,530,597,991, indicating a rise of approximately 5.5%[26] - The net cash flow from investing activities was -¥433,339,920, worsening from -¥400,882,530 in the previous period[26] - The net cash flow from financing activities was -¥30,251,198, compared to -¥40,270,646 in the previous period, showing an improvement[26] - Total assets increased by 3.04% to ¥58,364,865,856 from ¥56,643,545,143 at the end of the previous year[3] - Total liabilities decreased to CNY 14,807,235,062, down from CNY 15,885,367,579, a reduction of 6.8%[20] - Current assets rose to CNY 27,309,751,884, an increase of 6.5% from CNY 25,646,621,797[20] - Cash and cash equivalents increased to CNY 17,711,236,767, up from CNY 16,644,066,286, representing a growth of 6.4%[20] - Inventory increased to CNY 5,172,700,675, up 8.7% from CNY 4,757,425,283[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 92,191[8] - Smartco Development Limited and Magnifice (HK) Limited are the top two shareholders, holding 26.98% and 24.49% of shares, respectively[8] Research and Development - R&D investment in Q1 2025 was CNY 84.65 million, accounting for 10.28% of operating revenue, with new product launches in various diagnostic and medical fields[15] - The company has filed a total of 11,977 patent applications, with 5,973 patents granted, including 2,979 invention patents[15] - Research and development expenses were CNY 766,538,112, a decrease of 19.1% compared to CNY 947,431,880[23] Social Responsibility - The company organized 125 first aid training sessions, training 5,779 individuals, and has successfully treated 365 cardiac arrest patients using AEDs in public places[16] - The company donated medical equipment to support cleft lip and palate surgeries in underdeveloped regions, raising €9,441 for training projects in Africa through employee participation in charity events[17] International and Domestic Revenue - International business revenue grew by less than 5% year-over-year in Q1 2025, but the compound growth rate over the past two years exceeds 15%, with developing countries nearing 19%[13] - Domestic revenue declined over 20% year-over-year in Q1 2025, but increased by over 50% compared to Q4 2024, indicating a potential recovery starting in Q3 2025[14]